Bach‐Yen Nguyen

6.5k total citations · 2 hit papers
25 papers, 4.2k citations indexed

About

Bach‐Yen Nguyen is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Bach‐Yen Nguyen has authored 25 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 18 papers in Virology and 6 papers in Hepatology. Recurrent topics in Bach‐Yen Nguyen's work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (12 papers). Bach‐Yen Nguyen is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (12 papers). Bach‐Yen Nguyen collaborates with scholars based in United States, France and Germany. Bach‐Yen Nguyen's co-authors include Joseph J. Eron, Jeffrey Chodakewitz, Kathleen Squires, Margaret A. Fischl, Judith S. Currier, Michael D. Hughes, Louise Pedneault, John Phair, Lawrence Deyton and Judith Feinberg and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Hepatology.

In The Last Decade

Bach‐Yen Nguyen

25 papers receiving 4.1k citations

Hit Papers

A Controlled Trial of Two Nucleoside Analogues plus Indin... 1997 2026 2006 2016 1997 2015 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
    1997 2.1k citations Scott M. Hammer, Kathleen Squires et al. New England Journal of Medicine profile →
  2. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
    2015 386 citations Stefan Zeuzem, Reem Ghalib et al. Annals of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bach‐Yen Nguyen United States 20 3.4k 2.9k 1.0k 654 600 25 4.2k
Jonathan Schapiro United States 36 5.0k 1.5× 4.8k 1.7× 795 0.8× 479 0.7× 289 0.5× 83 5.9k
Maureen Myers United States 24 2.4k 0.7× 1.7k 0.6× 1.4k 1.4× 875 1.3× 306 0.5× 36 3.8k
Schlomo Staszewski Germany 41 6.1k 1.8× 5.1k 1.8× 1.5k 1.4× 378 0.6× 1.6k 2.6× 115 7.3k
David A. Cooper Australia 39 5.5k 1.6× 4.4k 1.5× 1.6k 1.5× 633 1.0× 1.4k 2.4× 118 7.1k
Peter Ruane United States 32 3.4k 1.0× 2.2k 0.8× 1.7k 1.6× 940 1.4× 745 1.2× 78 4.7k
Douglas L. Mayers United States 30 2.9k 0.8× 2.5k 0.9× 802 0.8× 412 0.6× 272 0.5× 90 3.9k
Lawrence Deyton United States 18 2.2k 0.6× 1.9k 0.7× 762 0.7× 236 0.4× 453 0.8× 36 3.5k
William Spreen United States 30 2.4k 0.7× 1.8k 0.6× 693 0.7× 148 0.2× 344 0.6× 80 3.6k
Katherine Huppler Hullsiek United States 31 1.6k 0.5× 1.2k 0.4× 1.1k 1.1× 328 0.5× 672 1.1× 52 2.9k
Pompeyo Viciana Spain 31 1.7k 0.5× 1.2k 0.4× 1.1k 1.1× 446 0.7× 408 0.7× 131 2.9k

Countries citing papers authored by Bach‐Yen Nguyen

Since Specialization
Citations

This map shows the geographic impact of Bach‐Yen Nguyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bach‐Yen Nguyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bach‐Yen Nguyen more than expected).

Fields of papers citing papers by Bach‐Yen Nguyen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bach‐Yen Nguyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bach‐Yen Nguyen. The network helps show where Bach‐Yen Nguyen may publish in the future.

Co-authorship network of co-authors of Bach‐Yen Nguyen

This figure shows the co-authorship network connecting the top 25 collaborators of Bach‐Yen Nguyen. A scholar is included among the top collaborators of Bach‐Yen Nguyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bach‐Yen Nguyen. Bach‐Yen Nguyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zamor, Philippe J., John M. Vierling, Reem Ghalib, et al.. (2018). Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. The American Journal of Gastroenterology. 113(6). 863–871. 2 indexed citations
3.
Reau, Nancy, Michael Robertson, Hwa-ping Feng, et al.. (2017). Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatology Communications. 1(8). 757–764. 9 indexed citations
4.
Zeuzem, Stefan, Reem Ghalib, K. Rajender Reddy, et al.. (2015). Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection. Annals of Internal Medicine. 163(1). 1–13. 386 indexed citations breakdown →
5.
Eron, Joseph J., David A. Cooper, Roy T. Steigbigel, et al.. (2014). Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection. Antiviral Therapy. 20(3). 307–315. 8 indexed citations
6.
Rockstroh, Jürgen K., Edwin DeJesus, Jeffrey L. Lennox, et al.. (2013). Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(1). 77–85. 167 indexed citations
7.
Kozal, Michael J., Sergio Lupo, Edwin DeJesus, et al.. (2012). A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results. HIV Clinical Trials. 13(3). 119–130. 70 indexed citations
8.
DeJesus, Edwin, Jürgen K. Rockstroh, Jeffrey L. Lennox, et al.. (2012). Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. HIV Clinical Trials. 13(4). 228–232. 26 indexed citations
9.
Gotuzzo, Eduardo, Martin Markowitz, Winai Ratanasuwan, et al.. (2012). Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 61(1). 73–77. 19 indexed citations
10.
Rizk, Matthew L., Yaming Hang, Wen‐Lin Luo, et al.. (2012). Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients. Antimicrobial Agents and Chemotherapy. 56(6). 3101–3106. 77 indexed citations
11.
Nguyen, Bach‐Yen, Robin Isaacs, Hedy Teppler, et al.. (2011). Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium. Annals of the New York Academy of Sciences. 1222(1). 83–89. 41 indexed citations
12.
Rockstroh, Jürgen K., Hedy Teppler, Jing Zhao, et al.. (2011). Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS. 25(11). 1365–1369. 23 indexed citations
13.
Teppler, Hedy, Deborah D. Brown, Randi Y. Leavitt, et al.. (2011). Long-Term Safety from the Raltegravir Clinical Development Program. Current HIV Research. 9(1). 40–53. 30 indexed citations
14.
Markowitz, Martin, Bach‐Yen Nguyen, Eduardo Gotuzzo, et al.. (2009). Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 52(3). 350–356. 94 indexed citations
15.
Iwamoto, Marian, Larissa Wenning, Bach‐Yen Nguyen, et al.. (2009). Effects of Omeprazole on Plasma Levels of Raltegravir. Clinical Infectious Diseases. 48(4). 489–492. 69 indexed citations
16.
Murray, John M., Sean Emery, Anthony D. Kelleher, et al.. (2007). Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 21(17). 2315–2321. 151 indexed citations
17.
Markowitz, Martin, Bach‐Yen Nguyen, Eduardo Gotuzzo, et al.. (2007). Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(2). 125–133. 317 indexed citations
18.
Markowitz, Martin, Javier O Morales-Ramirez, Bach‐Yen Nguyen, et al.. (2006). Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 509–515. 293 indexed citations
19.
Jankelevich, Shirley, Brigitta U. Mueller, Crystal L. Mackall, et al.. (2001). Long‐term Virologic and Immunologic Responses in Human Immunodeficiency Virus Type 1–Infected Children Treated with Indinavir, Zidovudine, and Lamivudine. The Journal of Infectious Diseases. 183(7). 1116–1120. 25 indexed citations
20.
Hammer, Scott M., Kathleen Squires, Michael D. Hughes, et al.. (1997). A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. New England Journal of Medicine. 337(11). 725–733. 2125 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Schapiro Breakdown of academic impact, for papers by Maureen Myers Breakdown of academic impact, for papers by Schlomo Staszewski Breakdown of academic impact, for papers by David A. Cooper Breakdown of academic impact, for papers by Peter Ruane Breakdown of academic impact, for papers by Douglas L. Mayers Breakdown of academic impact, for papers by Lawrence Deyton Breakdown of academic impact, for papers by William Spreen Breakdown of academic impact, for papers by Katherine Huppler Hullsiek Breakdown of academic impact, for papers by Pompeyo Viciana
Rankless by CCL
2026